Efficacy
At median follow up of 33.6 months in the intention to treat population, the median disease-free survival was 21.6 months (95% CI, 17.7 to 27.6) in the mFOLFIRINOX group vs 12.8 months (95% CI, 11.7 to 15.2) in the gemcitabine group (HR =0.58; 95% CI, 0.46 to 0.73; P<0.001). Disease-free survival rates at 1 year, 2 years, and 3 years were 69%, 47% and 39.7% in the mFOLFIRINOX group, as compared with 53.7%, 30.7% and 21.4% in the gemcitabine group.r
The median overall survival was 54.4 months (95% CI, 41.8 to not reached) in those receiving mFOLFIRINOX and 35.0 months (95% CI, 28.7 to 43.9) in those receiving gemcitabine (HR 0.64; 95% CI 0.48 to 0.86; P=0.003).r
Data remain immature with 61% patients being alive at the time of analysis. QOL data were not collected.r
Kaplan–Meier estimates of disease-free survival and overall survival in the intention-to-treat population, according to treatment groupr
© New Engl J Med 2018